HER2-Positive Breast Cancer Clinical Trials — 2026 Pipeline Tracker

Why HER2-positive breast cancer requires systematic trial monitoring

HER2-positive breast cancer — defined by HER2 protein overexpression (IHC 3+) or gene amplification (IHC 2+/FISH+) — affects approximately 15–20% of breast cancer patients and has been one of oncology's success stories since trastuzumab's approval in 1998. But the treatment landscape has undergone fundamental transformation in the past three years, driven by trastuzumab deruxtecan (T-DXd), which demonstrated unprecedented activity in HER2-high metastatic disease and validated a new HER2-low category spanning patients previously classified as HER2-negative.

With 239 recruiting trials across newly diagnosed, metastatic, and HER2-low settings, the HER2 breast cancer development landscape is one of the most active in solid tumor oncology. Key program categories to monitor in 2026:

• T-DXd (trastuzumab deruxtecan) combination trials — pairing with immunotherapy, CDK4/6 inhibitors, and endocrine therapy
• HER2-low and HER2-ultralow trial registrations as new biomarker-defined subgroups emerge
• Next-generation HER2-targeted ADCs from Asian and Western biotechs seeking to compete with T-DXd
• Neoadjuvant and adjuvant regimens optimizing post-trastuzumab emtansine (T-DM1) pathological CR
• CNS-penetrant HER2-targeted agents for brain metastases (tucatinib, neratinib, T-DXd CNS cohorts)
• HER2-targeted bispecific antibodies and T-cell engagers in early-phase development

The HER2-positive breast cancer treatment landscape in 2026

Trastuzumab deruxtecan — the dominant clinical development driver

Trastuzumab deruxtecan (T-DXd, Enhertu) has restructured HER2+ breast cancer clinical development more than any agent since trastuzumab itself. In HER2-high metastatic disease, DESTINY-Breast03 (NCT03529110) demonstrated a hazard ratio of 0.28 versus T-DM1, making T-DXd the new second-line standard of care. DESTINY-Breast04 (NCT03734029) extended T-DXd's activity to HER2-low (IHC 1+ or IHC 2+/FISH-) patients with hormone receptor-positive and HR-negative disease — the first time a HER2-directed agent showed OS benefit in this previously untargetable population. DESTINY-Breast06 (NCT04494425) pushed further to HER2-ultralow (IHC >0 to <1+), a definition that could encompass 60–70% of all HER2-negative breast cancers.

The pipeline consequence: dozens of trials are now exploring T-DXd in combination with CDK4/6 inhibitors (abemaciclib, ribociclib, palbociclib), checkpoint inhibitors (pembrolizumab, durvalumab), and endocrine agents — in first-line metastatic, neoadjuvant, and early-stage settings. Monitoring these registrations is essential for oncology professionals and investors in the HER2 franchise.

Competitive ADC landscape — the race to differentiate from T-DXd

T-DXd's commercial success ($3.7B annual revenue in 2025) has catalyzed a wave of next-generation HER2-targeting ADCs seeking differentiation through improved payload, linker chemistry, or manufacturing scalability. Active Phase 2/3 programs include:

• SHR-A1811 (Hengrui/Jiangsu Hengrui) — HER2-targeting ADC with topoisomerase I inhibitor payload; active Phase 3 trials in China and international cohorts across HER2-high and HER2-low subgroups
• MRG002 (Zymeworks/MacroGenics) — HER2-targeting ADC with MMAE payload; Phase 2 data presented in HER2+ metastatic breast cancer
• RC48 (Disitamab vedotin, RemeGen) — approved in China for HER2+ and HER2-low gastric cancer; Phase 2/3 data in breast cancer
• AZD5335 (AstraZeneca) — next-generation FOLR1/HER2 dual-targeting program entering Phase 3 (NCT07218809)

Each new ADC registration provides signal on where capital and development resources are flowing in the HER2 breast cancer competitive landscape.

Pertuzumab and tucatinib — established agents in new combinations

Pertuzumab (Perjeta, Roche/Genentech) plus trastuzumab plus docetaxel (CLEOPATRA) remains the standard first-line regimen in HER2+ metastatic breast cancer, and pertuzumab is now standard in the neoadjuvant setting based on NEOSPHERE and TRYPHAENA data. Active investigation centers on pertuzumab-based combinations with checkpoint inhibitors and novel chemotherapy backbones, and neoadjuvant regimen de-escalation strategies in low-risk HER2+ tumors (NCT07237256).

Tucatinib (Tukysa, Seagen/Pfizer) demonstrated OS benefit in combination with trastuzumab plus capecitabine in the HER2CLIMB trial (NCT02614794), establishing it as standard of care in later-line metastatic disease, particularly in patients with brain metastases. Multiple ongoing Phase 2/3 trials are testing tucatinib in combination with T-DXd (HER2CLIMB-04) and in earlier disease lines.

CNS disease — an urgent unmet need driving dedicated programs

Brain metastases occur in 30–50% of HER2+ metastatic breast cancer patients, and HER2-targeted systemic therapies with CNS penetration are among the highest-priority unmet needs in this disease. Tucatinib's 1-year CNS PFS of 24.9% versus 0% for standard therapy in HER2CLIMB established it as the standard for active CNS disease. T-DXd has demonstrated intracranial activity in DESTINY-Breast03 and dedicated CNS cohorts. Active trial development includes: CNS-optimized tucatinib combinations; pyrotinib (irreversible pan-HER TKI) from Chinese sponsors with intracranial activity data; and dedicated HER2+ breast brain metastasis protocols testing local plus systemic combinations.

HER2-low and HER2-ultralow — a rapidly evolving category

The DESTINY-Breast04 approval created an entirely new HER2-directed treatment population, and DESTINY-Breast06's data in HER2-ultralow is extending this further. Clinical trial monitoring in the HER2-low space requires a distinct approach: condition terms like "HER2-low", "HER2-ultralow", IHC 1+ filters, and FISH-negative selection criteria. Trial registrations in this category have increased substantially since 2023, with multiple sponsors seeking to demonstrate activity with their own HER2-targeting ADCs in this newly validated population.

Neoadjuvant optimization — a maturing field with de-escalation focus

Standard neoadjuvant chemotherapy plus dual HER2 blockade (trastuzumab plus pertuzumab) achieves pathological complete response in approximately 45–60% of HER2+ patients. Patients who achieve pCR can be maintained on trastuzumab, while residual disease patients receive T-DM1 adjuvant therapy (KATHERINE trial, NCT01772472). Active Phase 3 trials are exploring: neoadjuvant T-DXd replacing chemotherapy in HER2+ early-stage disease; de-escalation of chemotherapy in low-risk HER2+ patients; and biomarker-guided approaches using HER2 copy number, PIK3CA mutation, and immune markers to personalize neoadjuvant intensity.

Active Phase 3 trials in HER2-positive breast cancer (March 2026)

Trial	Agent / Strategy	Sponsor	Setting
NCT07377643	IBI354 + pertuzumab vs. taxane/trastuzumab/pertuzumab	Innovent Biopharmaceuticals	1L metastatic HER2+
NCT07205822	Dato-DXd (datopotamab deruxtecan) in HR+/HER2-	AstraZeneca	Metastatic HR+ (HER2-low eligible)
NCT07237256	Chemo de-escalation in HR+/HER2−, intermediate-risk early BC	UNICANCER	Neoadjuvant HER2−/HR+
NCT07281833	Olaparib + trastuzumab + chemotherapy	West German Study Group	Early-stage HER2+/gBRCA
NCT07196774	SHR-A1811 vs. standard therapies (neoadjuvant)	Jiangsu Hengrui	Neoadjuvant HER2+

Who uses HER2-positive breast cancer trial monitoring

Breast cancer pharma and biotech BD teams

Business development teams at AstraZeneca, Roche/Genentech, Daiichi Sankyo, Pfizer/Seagen, Novartis, and emerging ADC biotechs track competitor trial registrations continuously. With the HER2 breast cancer competitive landscape shifting rapidly across HER2-high, HER2-low, and HER2-ultralow subgroups, early intelligence on mechanism, patient selection, and combination strategy is essential for partnership decisions and asset valuation. A new Phase 2 trial registration from a Chinese ADC sponsor may precede public data by 18–24 months.

Breast medical oncologists and academic trialists

Oncologists at NCI-designated cancer centers — who both treat patients and conduct investigator-initiated research — track HER2 trial registrations to identify collaboration opportunities, understand the competitive protocol landscape before designing their own IITs, and match patients to appropriate trials. With T-DXd combinations, CNS-directed programs, and HER2-low trials all enrolling simultaneously, systematic monitoring is more efficient than manual ClinicalTrials.gov queries.

Oncology investors and portfolio managers

Fund managers with exposure to HER2+ breast cancer assets — AstraZeneca/Daiichi Sankyo's Enhertu franchise, Pfizer's Seagen-derived portfolio, and Chinese ADC biotechs entering global markets — monitor Phase 3 enrollment rates, protocol amendments, and early-phase trial registrations as leading indicators for clinical and regulatory milestones. Tracking which Phase 1 HER2 ADC programs from Chinese sponsors are expanding to international cohorts is a meaningful signal for asset prioritization.

Frequently asked questions

Can I track HER2-low and HER2-ultralow trials separately from HER2-positive trials?

Yes. On the Starter plan ($29/month), you can create up to 3 watchlists with distinct keyword sets. One profile might target "HER2-positive", "HER2+", "HER2 overexpressing" — and another specifically "HER2-low", "HER2-ultralow", "IHC 1+", "DESTINY-Breast" to track the rapidly expanding low-expression subgroup. This separation is increasingly important as trial populations and outcomes diverge between HER2-high and HER2-low patients.

Does DataLookout cover Chinese-sponsored HER2 ADC trials?

Yes. ClinicalTrials.gov includes all trials registered by international sponsors, including Chinese biotechs with US investigational sites or who register globally. Hengrui, Innovent, Jiangsu HengRui, and other Chinese sponsors active in HER2+ breast cancer register their Phase 2/3 trials on ClinicalTrials.gov, and DataLookout captures these registrations in the same daily pipeline as trials from Western sponsors.

How is DataLookout different from setting a ClinicalTrials.gov RSS alert for "HER2 breast cancer"?

ClinicalTrials.gov RSS alerts deliver raw, unfiltered data with no phase classification, sponsor type labels, or digest formatting. DataLookout provides the intelligence layer: you can filter by phase (Phase 2/3 only), status (recruiting only), and stack keywords (e.g., "HER2-positive" AND "neoadjuvant" AND NOT "HER3") to receive a focused daily digest. The result is a 5-minute morning read rather than an hour of manual search and classification.

Can I track T-DXd combination trials specifically?

Yes. Configure a watchlist with keywords like "trastuzumab deruxtecan", "T-DXd", "DS-8201", or "Enhertu" combined with your setting of interest. The Starter plan supports keyword stacking — so you can create one profile for T-DXd combinations and a second for all other HER2-targeted ADCs, keeping the two intelligence streams cleanly separated.